Medicare's Maximum Fair Price Shakes Up Pharmacy Dispensing Economics
Milliman examines how Medicare Part D's Maximum Fair Price (MFP) program, created under the Inflation Reduction Act, is altering pharmacy stocking and dispensing incentives as manufacturers choose different refund benchmarks for negotiated drugs. The analysis finds that the refund mechanism design, more than the negotiated price itself, determines whether dispensing specialty drugs remains viable for small and independent pharmacies, with ripple effects across entire therapeutic classes. While centered on Medicare rather than Medicaid, the pharmacy reimbursement and specialty drug dynamics discussed carry indirect relevance for Medicaid pharmacy benefit managers and managed care plans monitoring parallel drug pricing pressures.
This is outside commentary from Milliman, not part of Medicaid Monitor's independently scored news coverage.